Evaluate Pharma

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2028 for the global life science industry.

[Evaluate Pharma @evaluatepharma]

Tracking thousands of pharma assets manually is too slow and error-prone. Ryan Lu explains how we use proprietary data and expert validation to move from reactive to proactive decision-making.

Get a clear view of the landscape here: https://t.co/j0Ho3DBdQl

[Evaluate Pharma @evaluatepharma]

The deal-making landscape is shifting fast. https://t.co/JZpHg9zasd

2025 saw $269.5B in alliances, $201B+ in M&A with mega deals, and $83.6B in financing—fewer deals, bigger bets. Medtech is rebounding, too.

[Evaluate Pharma @evaluatepharma]

The World Preview 2026 webinar provides a clear view of the pharma landscape for the next 5 years, using industry-standard forecasting models trusted by leading investors and strategists.

📅 June 16 | 3pm London | 10am New York

Register now: https://t.co/M8OQ5gGii6

[Evaluate Pharma @evaluatepharma]

Understanding what’s coming next in pharma starts with the right perspective. In our latest interview, Ryan Lu compiled the latest trends in upcoming drug approvals for a group purchasing organization.

Dive into the interview for the complete insight: https://t.co/QH7aq60gRH

[Evaluate Pharma @evaluatepharma]

What does it really take to stay ahead in today’s development landscape? In this expert interview, Ryan Lu breaks down how structured pipeline tracking and data-led analysis are helping organizations move from reactive to proactive decision-making: https://t.co/9GXuP7zUNT

[Evaluate Pharma @evaluatepharma]

Pre-ASCO signals are already here—oncology’s next phase is taking shape.

From Datroway & Giredestrant to B7-H4 and bispecifics, our Pre-ASCO 2026 report highlights the assets and trends set to define the year ahead.

Get ahead of the headlines: https://t.co/acMyLS4VqZ

[Evaluate Pharma @evaluatepharma]

Biopharma entered 2026 with cautious optimism, but where do we actually stand?

The data shows a complex picture: M&A surged in March and IPO activity paused after a fast start, while VC remains disciplined on risk.

See the full Q1 picture: https://t.co/fuapC5D34C

[Evaluate Pharma @evaluatepharma]

Billions in pharma sales are at risk as patents expire. Forecasting teams are key—shaping strategy from generics impact to portfolio priorities.

See how their role is evolving: https://t.co/YqM8vfbIF1

[Evaluate Pharma @evaluatepharma]

Where are the biggest biopharma deals happening? https://t.co/CChNGopD7c

Oncology leads (37% of partnerships), with autoimmune, immunology, and CNS gaining momentum. Billion-dollar alliances are focusing on these high-value areas.

[Evaluate Pharma @evaluatepharma]

The future of pharma is changing fast.

Get the clarity you need with the World Preview 2026 webinar, combining forecasts, competitive intelligence, and market data into one view of what is next.

📅 June 16 | 3pm London | 10am New York

Secure your spot: https://t.co/jSNaazTz8W

[Evaluate Pharma @evaluatepharma]

From top‑selling drugs to the most valuable pipeline assets, here’s what will shape 2026.

Explore the full Preview Report: https://t.co/9wHG6CM5C2

[Evaluate Pharma @evaluatepharma]

A good read from Fierce Biotech on how China-based biotechs are approaching pricing as buyers rely more on AI and local market insight. https://t.co/S4M0bCF1yJ

Backed by Evaluate & @NorstellaCo data—worth a 5-min read. https://t.co/Ra0Aca7u0E

[Evaluate Pharma @evaluatepharma]

By the early 2030s, orphan drugs could make up ~20% of the prescription drug market. What’s driving the forecast? Watch our webinar to find out.

"Orphan Drugs: A safe(r) passage amid stormy waters?" webinar: https://t.co/Jsq4RaPpSp

[Evaluate Pharma @evaluatepharma]

No two assets — or decisions — are the same. From early‑stage evaluation to post‑launch forecasting, Sheila Li works with clients to build customized frameworks that support confident, data‑driven choices at every stage of the asset lifecycle. https://t.co/H6HVChPv6k

[Evaluate Pharma @evaluatepharma]

DOWNLOAD: The lines between pharma and biotech are blurring. As funding tightens and policy shifts, biotechs grow leaner and more independent, while pharma explores new models and direct-to-patient channels.

Preview the trends in our summary: https://t.co/0M3E3VxQ3k

[Evaluate Pharma @evaluatepharma]

FDA oversight remains a key factor in orphan drug outlooks. How regulatory assumptions are built into projections through 2032 is discussed in the on‑demand "Orphan Drugs: A safe(r) passage amid stormy waters?" webinar: https://t.co/t7CHdas65p

[Evaluate Pharma @evaluatepharma]

The biggest outlook in pharma is back.

Join the World Preview 2026 webinar for forecasts to 2032 and insights to stay ahead.

📅 June 16 | 3pm London | 10am New York

🔗 https://t.co/QyxyaST0QF

[Evaluate Pharma @evaluatepharma]

Biopharma deal-making didn’t slow in 2025—it evolved. https://t.co/pKDYVQN9mN

$269.5B in alliances (+37% avg deal size) and $201.2B in M&A driven by mega deals. Q4 led across the board. Momentum is building, not cooling.

[Evaluate Pharma @evaluatepharma]

The biggest biopharma M&A deals don’t just reflect the market; they define it. Q1 saw a late surge in dealmaking, with multiple $1B+ acquisitions reshaping portfolios. From oncology to rare diseases, these bets signal what’s next. Download: https://t.co/Mx9yxG6Yzc

[Evaluate Pharma @evaluatepharma]

Q1 2026 biopharma: momentum is back… but caution is still driving decisions.

-M&A up 32% QoQ
-IPOs hit $1.81B (faded by March)
-VC steady at $7.94B

Capital is available, but deployed more selectively than ever. See where conviction is building: https://t.co/fqmAcNoAX0